Morbidity and PSA control of EBRT plus LDR brachytherapy boost for intermediate and high risk prostate cancer

Brachytherapy ◽  
2008 ◽  
Vol 7 (2) ◽  
pp. 190
Author(s):  
Bridget F. Koontz ◽  
Carol A. Hahn ◽  
Mitchell S. Anscher
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
High Risk Prostate Cancer ◽  
Ldr Brachytherapy ◽  
Risk Prostate Cancer ◽  
Brachytherapy Boost

Low Dose Rate Brachytherapy Boost for High-risk Prostate Cancer: An Evidence-based Approach

2020 ◽  
Vol 32 (7) ◽  
pp. e162
Author(s):  
C. Mikropoulos ◽  
S. Otter ◽  
C. Perna ◽  
S. Khaksar ◽  
A. Franklin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Dose Rate ◽  
Low Dose ◽  
Evidence Based ◽  
Low Dose Rate ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Brachytherapy Boost ◽  
Low Dose Rate Brachytherapy

I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes

Brachytherapy ◽  
2020 ◽  
Vol 19 (5) ◽  
pp. 567-573
Author(s):  
Nelson N. Stone ◽  
Vassilios M. Skouteris ◽  
Barry S. Rosenstein ◽  
Richard G. Stock
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer ◽  
Brachytherapy Boost
Sign in / Sign up

Export Citation Format

Share Document